Current Report Filing (8-k)
December 09 2015 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 3, 2015
XOMA CORPORATION
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE |
|
001-14710 |
|
52-2154066 |
(State of
incorporation) |
|
(Commission
File No.) |
|
(IRS Employer
Identification No.) |
XOMA Corporation
2910 Seventh Street
Berkeley, CA 94710
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (510) 204-7200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 1.01 |
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. |
On December 3, 2015, XOMA (US) LLC (the
Company or XOMA), as a successor-in-interest of XOMA Ireland Limited and Pfizer Inc. (Pfizer), entered into a settlement and amended license agreement (the Agreement), pursuant to which XOMA granted a
fully-paid, royalty-free, worldwide, irrevocable, non-exclusive license rights to XOMAs patented bacterial cell expression (BCE) technology for phage display and other research, development and manufacturing of antibody products for an
upfront, non-dilutive cash payment by Pfizer of $3.8 million in full satisfaction of all obligations to XOMA under the 2007 Agreement (defined below), including but not limited to potential milestone, royalty and other fees under the 2007
Agreement.
Under the terms of the original License Agreement, effective as of August 27, 2007, by and between XOMA Ireland Limited and Pfizer Inc.
(the 2007 Agreement), XOMA received an upfront, non-dilutive cash payment of $30 million and was eligible for potential milestone, royalty and other fees on future sales of all products subject to this license, including products
currently in late-stage clinical development.
The description of the Agreement contained herein does not purport to be complete and is qualified in its
entirety by reference to the complete text of the Agreement, a copy of which will be filed as an exhibit to the Companys Annual Report on Form 10-K for the period ending December 31, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: December 9, 2015 |
|
|
|
XOMA Corporation |
|
|
|
|
|
|
|
|
By: |
|
/s/ Russell J. Wood |
|
|
|
|
|
|
Russell J. Wood |
|
|
|
|
|
|
Sr. Corporate Counsel and Corporate Secretary |
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024